Skip to main content
Premium Trial:

Request an Annual Quote

PE Files for Follow-on Celera Stock Offering

Premium

R

OCKVILLE, Md.--PE announced that it has filed with the Securities and Exchange Commission for a follow-on public offering of 1.615 million shares of its Celera Genomics common stock. The number of shares to be sold does not reflect the previously announced two-for-one Celera stock split effective February 18. The net proceeds from the offering are intended primarily to fund Celera’s new product and technology development activities in functional genomics, with an emphasis on proteomics, and personalized health/medicine. Celera also intends to use the capital for general corporate purposes, including possible acquisitions, alliances, or collaborations.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.